FDA Approves Datroway for HR-Positive Breast Cancer

The FDA has approved Datroway, a new chemotherapy drug for adults with unresectable or metastatic hormone receptor-positive, HER2-negative breast cancer, which accounts for about 70% of breast cancer cases. This drug, classified as an antibody-drug conjugate, targets cancer cells more directly than standard chemotherapy, providing a promising option for patients who have already undergone prior treatments. In related advancements, the NEOSENTITURK MF-1803 trial has shown that sentinel lymph node biopsy (SLNB) can be a viable alternative to targeted axillary dissection for patients who achieve node-negative status after neoadjuvant chemotherapy, thus reducing surgical morbidity without compromising oncological outcomes. The trial's findings suggest that SLNB effectively detects microscopic disease while maintaining low recurrence rates. Additionally, independent studies on ProSense® cryoablation technology were showcased at a recent conference, highlighting its safety and efficacy as a minimally invasive treatment option for breast cancer. These developments reflect ongoing innovations in breast cancer treatment, offering patients more tailored and less invasive options.